These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 8426301

  • 1. New developments in the clinical use of didanosine.
    Kahn J.
    J Acquir Immune Defic Syndr (1988); 1993; 6 Suppl 1():S47-50. PubMed ID: 8426301
    [Abstract] [Full Text] [Related]

  • 2. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC, Martin ES.
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [Abstract] [Full Text] [Related]

  • 3. Didanosine.
    Shelton MJ, O'Donnell AM, Morse GD.
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [Abstract] [Full Text] [Related]

  • 4. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [Abstract] [Full Text] [Related]

  • 5. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
    AIDS; 1996 Jul; 10(8):867-80. PubMed ID: 8828744
    [Abstract] [Full Text] [Related]

  • 6. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [Abstract] [Full Text] [Related]

  • 8. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H, Arasteh K, Staszewski S, Ruf B, Stellbrink HJ, Schrappe M, Stoehr A, Haase W, Schomaker U, von Eisenhart Rothe B.
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE.
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [Abstract] [Full Text] [Related]

  • 10. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP, Liebman HA.
    N Engl J Med; 1990 May 10; 322(19):1340-5. PubMed ID: 2139174
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M, Soriano V, García-Lerma G, González-Lahoz J.
    An Med Interna; 1998 Mar 10; 15(3):145-7. PubMed ID: 9567422
    [Abstract] [Full Text] [Related]

  • 12. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
    Delta Coordinating Committee.
    HIV Med; 2001 Jul 10; 2(3):181-8. PubMed ID: 11737399
    [Abstract] [Full Text] [Related]

  • 13. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
    Reichman RC, Tejani N, Lambert JL, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R.
    Antiviral Res; 1993 Apr 10; 20(4):267-77. PubMed ID: 8097906
    [Abstract] [Full Text] [Related]

  • 14. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C, Tchatchueng Mbougua JB, Ngom Guèye NF, Etard JF, Diouf A, Landman R, Molinari N, Girard PM, Sow PS, Ndoye I, Delaporte E, ANRS 1215/1290 Study Group.
    Trop Med Int Health; 2011 Feb 10; 16(2):217-22. PubMed ID: 21087377
    [Abstract] [Full Text] [Related]

  • 15. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
    Kelleher T, Cross A, Dunkle L.
    Clin Ther; 1999 Jul 10; 21(7):1182-92. PubMed ID: 10463516
    [Abstract] [Full Text] [Related]

  • 16. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B, Wintergerst U, Notheis G, Eberle J, Gürtler L, Belohradsky BH.
    J Pediatr; 1997 Feb 10; 130(2):293-9. PubMed ID: 9042135
    [Abstract] [Full Text] [Related]

  • 17. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
    Raskino C, Pearson DA, Baker CJ, Lifschitz MH, O'Donnell K, Mintz M, Nozyce M, Brouwers P, McKinney RE, Jimenez E, Englund JA.
    Pediatrics; 1999 Sep 10; 104(3):e32. PubMed ID: 10469815
    [Abstract] [Full Text] [Related]

  • 18. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
    Delta Coordinating CommitteeMedical Research Council Clinical Trials Unit, University College London Medical School, UK., Delta Virology Committee.
    AIDS; 1999 Jan 14; 13(1):57-65. PubMed ID: 10207545
    [Abstract] [Full Text] [Related]

  • 19. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P.
    AIDS Res Hum Retroviruses; 1998 Dec 20; 14(18):1653-9. PubMed ID: 9870319
    [Abstract] [Full Text] [Related]

  • 20. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.